Subclinical pregnancy loss in clomiphene citrate-treated women

B. G. Bateman, L. A. Kolp, W. C. Nunley, R. Felder, B. Burkett

Research output: Contribution to journalArticle

Abstract

Objective: To ascertain the subclinical pregnancy loss rate in clomiphene citrate (CC)-treated infertile women compared with women of normal fertility. Design: Following a prospective format, serum samples were taken during the luteal phase of 92 menstrual cycles associated with CC treatment and 47 cycles in normal women. Human chorionic gonadotropin (hCG) assay sensitivity was 0.25 IU/L. Human chorionic gonadotropin assay was validated against 95 nonpregnant cycles. Criterion for pregnancy was a single serum sample ≥ 0.5 IU/L. Setting: All subjects were under clinical management at the University of Virginia Health Sciences Center. Patients and Participants: Patients undergoing CC induction of ovulation with satisfactory ovulatory response were candidates for the study group (n = 34). Control subjects of proven normal fertility were recruited (n = 22). Nonpregnant control subjects were sexually abstinent or had been surgically sterilized (n = 89). Intervention: A serum sample was taken during the late luteal phase of all subjects. Results: Thirteen percent of CC-treated cycles and 4.3% of normal control cycles were subclinical losses (P = 0.09). Fifty percent of CC-induced pregnancies were subclinical losses compared with 16.6% of normal control pregnancies (P = 0.05). Of CC patients who had at least one subclinical loss 47.6% later conceived a term pregnancy compared with 15.3% who did not have a subclinical loss (P = 0.06). Conclusion: Subclinical pregnancy loss is more common in CC-treated women than normal women and may be a predictor of subsequent normal conception.

Original languageEnglish (US)
Pages (from-to)25-27
Number of pages3
JournalFertility and Sterility
Volume57
Issue number1
StatePublished - 1992
Externally publishedYes

Fingerprint

Clomiphene
Pregnancy
Luteal Phase
Chorionic Gonadotropin
Fertility
Serum
Ovulation Induction
Pregnancy Rate
Health

Keywords

  • clomiphene citrate
  • Subclinical abortion

ASJC Scopus subject areas

  • Obstetrics and Gynecology

Cite this

Bateman, B. G., Kolp, L. A., Nunley, W. C., Felder, R., & Burkett, B. (1992). Subclinical pregnancy loss in clomiphene citrate-treated women. Fertility and Sterility, 57(1), 25-27.

Subclinical pregnancy loss in clomiphene citrate-treated women. / Bateman, B. G.; Kolp, L. A.; Nunley, W. C.; Felder, R.; Burkett, B.

In: Fertility and Sterility, Vol. 57, No. 1, 1992, p. 25-27.

Research output: Contribution to journalArticle

Bateman, BG, Kolp, LA, Nunley, WC, Felder, R & Burkett, B 1992, 'Subclinical pregnancy loss in clomiphene citrate-treated women', Fertility and Sterility, vol. 57, no. 1, pp. 25-27.
Bateman BG, Kolp LA, Nunley WC, Felder R, Burkett B. Subclinical pregnancy loss in clomiphene citrate-treated women. Fertility and Sterility. 1992;57(1):25-27.
Bateman, B. G. ; Kolp, L. A. ; Nunley, W. C. ; Felder, R. ; Burkett, B. / Subclinical pregnancy loss in clomiphene citrate-treated women. In: Fertility and Sterility. 1992 ; Vol. 57, No. 1. pp. 25-27.
@article{3914612312144a9ea27bbb05d0539217,
title = "Subclinical pregnancy loss in clomiphene citrate-treated women",
abstract = "Objective: To ascertain the subclinical pregnancy loss rate in clomiphene citrate (CC)-treated infertile women compared with women of normal fertility. Design: Following a prospective format, serum samples were taken during the luteal phase of 92 menstrual cycles associated with CC treatment and 47 cycles in normal women. Human chorionic gonadotropin (hCG) assay sensitivity was 0.25 IU/L. Human chorionic gonadotropin assay was validated against 95 nonpregnant cycles. Criterion for pregnancy was a single serum sample ≥ 0.5 IU/L. Setting: All subjects were under clinical management at the University of Virginia Health Sciences Center. Patients and Participants: Patients undergoing CC induction of ovulation with satisfactory ovulatory response were candidates for the study group (n = 34). Control subjects of proven normal fertility were recruited (n = 22). Nonpregnant control subjects were sexually abstinent or had been surgically sterilized (n = 89). Intervention: A serum sample was taken during the late luteal phase of all subjects. Results: Thirteen percent of CC-treated cycles and 4.3{\%} of normal control cycles were subclinical losses (P = 0.09). Fifty percent of CC-induced pregnancies were subclinical losses compared with 16.6{\%} of normal control pregnancies (P = 0.05). Of CC patients who had at least one subclinical loss 47.6{\%} later conceived a term pregnancy compared with 15.3{\%} who did not have a subclinical loss (P = 0.06). Conclusion: Subclinical pregnancy loss is more common in CC-treated women than normal women and may be a predictor of subsequent normal conception.",
keywords = "clomiphene citrate, Subclinical abortion",
author = "Bateman, {B. G.} and Kolp, {L. A.} and Nunley, {W. C.} and R. Felder and B. Burkett",
year = "1992",
language = "English (US)",
volume = "57",
pages = "25--27",
journal = "Fertility and Sterility",
issn = "0015-0282",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Subclinical pregnancy loss in clomiphene citrate-treated women

AU - Bateman, B. G.

AU - Kolp, L. A.

AU - Nunley, W. C.

AU - Felder, R.

AU - Burkett, B.

PY - 1992

Y1 - 1992

N2 - Objective: To ascertain the subclinical pregnancy loss rate in clomiphene citrate (CC)-treated infertile women compared with women of normal fertility. Design: Following a prospective format, serum samples were taken during the luteal phase of 92 menstrual cycles associated with CC treatment and 47 cycles in normal women. Human chorionic gonadotropin (hCG) assay sensitivity was 0.25 IU/L. Human chorionic gonadotropin assay was validated against 95 nonpregnant cycles. Criterion for pregnancy was a single serum sample ≥ 0.5 IU/L. Setting: All subjects were under clinical management at the University of Virginia Health Sciences Center. Patients and Participants: Patients undergoing CC induction of ovulation with satisfactory ovulatory response were candidates for the study group (n = 34). Control subjects of proven normal fertility were recruited (n = 22). Nonpregnant control subjects were sexually abstinent or had been surgically sterilized (n = 89). Intervention: A serum sample was taken during the late luteal phase of all subjects. Results: Thirteen percent of CC-treated cycles and 4.3% of normal control cycles were subclinical losses (P = 0.09). Fifty percent of CC-induced pregnancies were subclinical losses compared with 16.6% of normal control pregnancies (P = 0.05). Of CC patients who had at least one subclinical loss 47.6% later conceived a term pregnancy compared with 15.3% who did not have a subclinical loss (P = 0.06). Conclusion: Subclinical pregnancy loss is more common in CC-treated women than normal women and may be a predictor of subsequent normal conception.

AB - Objective: To ascertain the subclinical pregnancy loss rate in clomiphene citrate (CC)-treated infertile women compared with women of normal fertility. Design: Following a prospective format, serum samples were taken during the luteal phase of 92 menstrual cycles associated with CC treatment and 47 cycles in normal women. Human chorionic gonadotropin (hCG) assay sensitivity was 0.25 IU/L. Human chorionic gonadotropin assay was validated against 95 nonpregnant cycles. Criterion for pregnancy was a single serum sample ≥ 0.5 IU/L. Setting: All subjects were under clinical management at the University of Virginia Health Sciences Center. Patients and Participants: Patients undergoing CC induction of ovulation with satisfactory ovulatory response were candidates for the study group (n = 34). Control subjects of proven normal fertility were recruited (n = 22). Nonpregnant control subjects were sexually abstinent or had been surgically sterilized (n = 89). Intervention: A serum sample was taken during the late luteal phase of all subjects. Results: Thirteen percent of CC-treated cycles and 4.3% of normal control cycles were subclinical losses (P = 0.09). Fifty percent of CC-induced pregnancies were subclinical losses compared with 16.6% of normal control pregnancies (P = 0.05). Of CC patients who had at least one subclinical loss 47.6% later conceived a term pregnancy compared with 15.3% who did not have a subclinical loss (P = 0.06). Conclusion: Subclinical pregnancy loss is more common in CC-treated women than normal women and may be a predictor of subsequent normal conception.

KW - clomiphene citrate

KW - Subclinical abortion

UR - http://www.scopus.com/inward/record.url?scp=0026597526&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026597526&partnerID=8YFLogxK

M3 - Article

C2 - 1730325

AN - SCOPUS:0026597526

VL - 57

SP - 25

EP - 27

JO - Fertility and Sterility

JF - Fertility and Sterility

SN - 0015-0282

IS - 1

ER -